Family medicine clinicians prescribing GLP-1 receptor agonists such as semaglutide must be prepared to evaluate and address the multiple patient-specific factors that can attenuate expected weight loss responses, including subtherapeutic dosing, dietary composition, concomitant medications, and underlying metabolic or hormonal conditions. When patients present with inadequate response, a structured clinical reassessment is warranted rather than premature discontinuation, as modifiable contributors are frequently identifiable. Understanding the heterogeneity of treatment response supports more individualized titration strategies and improves long-term patient retention and outcomes in obesity medicine.
The available abstract does not contain sufficient clinical data to support a rigorous physician-level summary. The source appears to be a consumer news article from the Daily Herald rather than a peer-reviewed study, and the abstract excerpt provides no quantitative findings, no study population characteristics, no methodology, and no outcome measures beyond a reference to semaglutide agents such as Ozempic and Wegovy acting on the GLP-1 pathway.
To write an accurate, evidence-based clinical summary of the type requested, the full article text or an actual study abstract with reported endpoints, sample sizes, and statistical results would be required. If you have access to the complete article or a linked primary source, please provide that content and a full summary can be generated from it.
GLP-1 receptor agonists like semaglutide are effective tools for weight management, but not every patient achieves the same degree of weight loss, and individual response can vary significantly based on factors such as diet, activity level, medication adherence, and underlying metabolic conditions. Some patients may experience a plateau or suboptimal response even when taking the medication consistently, which is a normal part of the pharmacological landscape rather than a treatment failure. Clinicians should set realistic expectations upfront and monitor patients regularly to distinguish between true non-response and modifiable lifestyle or adherence barriers. In a family medicine setting, proactively scheduling follow-up visits at 12 and 24 weeks after initiation gives providers a structured opportunity to reassess dosing, address side effects, and reinforce behavioral strategies before patients become discouraged and discontinue therapy.
“The conversation around GLP-1 non-response is one I have with patients almost weekly, and it deserves more clinical nuance than most coverage provides. Factors like baseline insulin resistance, gut microbiome variability, dietary composition, and even injection technique can meaningfully blunt a patient’s response to semaglutide. What frustrates me is when patients interpret inadequate weight loss as personal failure rather than a signal that we need to adjust the clinical strategy. In practice, I make a point of setting this expectation early: if we are not seeing the response we want at an appropriate dose, that is a diagnostic clue, not a dead end.”
? Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
Why am I not losing weight even though I am taking a GLP-1 medication like Ozempic or Wegovy?
Several factors can limit weight loss on GLP-1 therapy, including insufficient dose, dietary habits that offset the appetite-suppressing effects, and underlying metabolic conditions. Your prescribing physician should review your current dose, lifestyle factors, and any medical issues that might be interfering with your response.
How long does it typically take to see weight loss results on semaglutide?
Most patients begin to notice meaningful weight loss within 8 to 12 weeks, though the full effect often develops over 6 to 12 months as the dose is gradually increased. Patience and consistent adherence to both the medication and lifestyle changes are important during this period.
Does what I eat affect how well my GLP-1 medication works?
Yes, diet plays a significant role in your overall results even though GLP-1 medications reduce appetite. Consuming high-calorie, highly processed foods can counteract the caloric deficit the medication helps create, slowing or stalling weight loss.
Can other medications I take interfere with GLP-1 therapy?
Certain medications, including corticosteroids, some antidepressants, antipsychotics, and insulin secretagogues, can promote weight gain or affect blood sugar regulation in ways that work against GLP-1 therapy. Your doctor should conduct a full medication review to identify any potential conflicts.
Is there a reason my body might simply not respond to semaglutide?
A small percentage of patients are considered non-responders, which may relate to genetic variability in GLP-1 receptor expression or differences in gut hormone signaling. If you have shown no meaningful response after reaching an adequate dose over several months, your physician may consider alternative therapeutic approaches.
Does sleep or stress affect my weight loss results on GLP-1 medications?
Poor sleep and chronic stress elevate cortisol levels, which can increase appetite, promote fat storage, and directly undermine the benefits of GLP-1 therapy. Addressing sleep hygiene and stress management is a clinically important part of a comprehensive weight loss plan.
Should I also be exercising while on a GLP-1 medication?
Physical activity improves insulin sensitivity, preserves lean muscle mass, and enhances the metabolic benefits of GLP-1 therapy. Resistance training in particular is recommended because significant caloric restriction combined with GLP-1 use can sometimes lead to muscle loss without it.
Could a thyroid problem be preventing me from losing weight on semaglutide?
Hypothyroidism reduces metabolic rate and can significantly blunt weight loss even in patients taking effective GLP-1 medications. Your physician should check thyroid function as part of a standard workup if weight loss is not progressing as expected.
What should I do if I have been on semaglutide for several months without losing weight?
You should schedule a thorough evaluation with your physician to reassess your dose, review your dietary intake, check for contributing medical conditions, and evaluate whether the current medication is the right fit for your metabolic profile. Simply continuing the same approach without investigation is unlikely to produce different results.
Are GLP-1 medications like Wegovy and Ozempic the same drug, and does it matter which one I take for weight loss?
Both Ozempic and Wegovy contain semaglutide, but they are FDA-approved for different indications and are available at different maximum doses. Wegovy is approved specifically for chronic weight management and is titrated to a higher maintenance dose than Ozempic, which matters clinically when weight loss is the primary treatment goal.
